Home The Active Ingredient Matrix Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan)

Formulation Intelligence

Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan)

Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan).

This yeast-derived polysaccharide functions as a biological response modifier by binding to Dectin-1 receptors on macrophages and neutrophils, thereby priming the innate immune system without inducing pro-inflammatory cytokine overproduction.

Verified Molecular Profiling (NIH PubChem)

PubChem CID

439261

Molecular Weight

856.5 g/mol

XLogP3 (Lipophilicity)

-8.8

IUPAC Name

[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-[[[(2R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl] hydrogen phosphate

Pharmacokinetic Synergies & Enhancers

Proven Synergy Pairings

  • Vitamin C for enhanced phagocytic activity
  • Vitamin D3 for synergistic modulation of adaptive immune responses

Biological Formulation Enhancers

  • Protease enzymes for improved liberation from the yeast cell wall matrix
  • Ascorbic acid for facilitating macrophage oxidative burst capacity

Delivery System Constraints & Modeling

Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan) across standard consumer modalities.

💊 Standard Capsules

The high bulk density and potential hygroscopicity of yeast-derived glucans require careful excipient selection to prevent clumping and ensure consistent flow during encapsulation.

🍬 Gummy & Pectin Formats

High molecular weight polysaccharides like beta-glucan can interfere with pectin cross-linking, resulting in a grainy texture or compromised structural integrity of the gummy matrix.

🔬 Thin-Film Oral Strips

The high therapeutic dosage required for effective immunomodulation typically exceeds the limited payload capacity of thin-film matrices, which are generally restricted to doses under 100mg.

For Brand Founders

Formulate with Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan)

Ready to launch a product featuring Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.

Build Science-Backed Formulation

Efficacy Evidence

Maximize Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan) Bioavailability

Need absolute proof that your Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.

Simulate Bioavailability

For R&D Labs & CDMOs

Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan) Degradation Testing

Is your Saccharomyces cerevisiae (Beta-1,3/1,6-D-Glucan) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.

Model Active Degradation